James Noble, Director at Adaptimmune Therapeutics PLC (ADAP), sold 500,000 shares at $9.33 ($4.7M) on 2020-05-29, disclosed to the SEC on 2020-06-02.
Open-market sale of $4.7M ADAP by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| CRGN | BUY | 2007-05-09 | $57K | — | Filing → |